Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aspirin Population For MI Prevention Rests On “Floating” Factors – Temple

This article was originally published in The Tan Sheet

Executive Summary

Bayer will have to bolster its evidence that aspirin use has an actual benefit for primary prevention of myocardial infarction, the firm was told during an April 30 FDA feedback meeting

You may also be interested in...

Bayer Will Submit More Data To FDA On Aspirin MI Prevention Labeling

Bayer will submit additional data on subpopulation risks associated with aspirin therapy to support its citizen petition requesting amended professional labeling for primary prevention of myocardial infarction

Non-Fatal MI Prevention Indication For Aspirin May Cause Bayer Less Pain

Bayer may have a better shot of gaining FDA approval of expanded professional labeling for aspirin by pursuing an indication for prevention of non-fatal myocardial infarction. The firm got a negative advisory committee vote for prevention of all MIs at a Dec. 8 meeting

People In Brief

Perrigo promotes in pricing, planning





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts